US Tariffs on Pharmaceutical Products from Mexico — 10% (2026)

Pharmaceutical Products from Mexico represent an important segment of bilateral trade, with approximately $779B in total bilateral trade.

Following the Supreme Court's landmark February 20, 2026 decision striking down IEEPA tariffs, imports of pharmaceutical products from Mexico are now subject to a 10% tariff under Section 122 of the Trade Act of 1974, effective February 24, 2026.

This 10% rate has a built-in expiration: Section 122 limits presidential tariff authority to 150 days, meaning the tariff expires approximately July 24, 2026 without congressional renewal.

Pharmaceutical Products (HTS Chapter 30) generally enter duty-free at the MFN level, with the Section 122 tariff as the primary duty. No additional Section 232 or Section 301 surcharges apply to most products in this category from Mexico.

Mexico is party to the USMCA, which may provide preferential or duty-free access for qualifying pharmaceutical products. Importers should verify rules of origin requirements to take advantage of preferential rates.

Key products in HTS Chapter 30 imported from Mexico include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.